Palliative goals, patient selection, and perioperative platelet management: Outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic

Cancer

Volumn 107, Issue 2, 2006, Pages 361-370

  Mesa, Ruben A ^a   Nagorney, David S ^a   Schwager, Susan ^a   Allred, Jacob ^b   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC CANCER CENTER   (United States)

Author keywords

Myelofibrosis; Myeloid metaplasia; Outcome; Platelet count; Splenectomy; Technique

Indexed keywords

ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; MYELOID METAPLASIA; OUTCOMES RESEARCH; PALLIATIVE THERAPY; PATIENT SELECTION; PERIOPERATIVE PERIOD; PORTAL HYPERTENSION; PRIORITY JOURNAL; SPLENECTOMY; SPLENOMEGALY; SURGICAL RISK; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOPHERESIS; THROMBOSIS; TREATMENT INDICATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GOALS; HUMANS; MALE; MIDDLE AGED; MYELOFIBROSIS; MYELOID METAPLASIA; PALLIATIVE CARE; PATIENT SELECTION; PERIOPERATIVE CARE; PLATELET COUNT; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; SPLENECTOMY; THROMBOCYTOSIS; TREATMENT OUTCOME;

EID: 33745811661     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22021     Document Type: Article

References (20)

1. Fialkow PJ. Stem cell origin of human myeloid blood cell neoplasms. Verh Dtsch Ges Pathol. 1990;74:43-47.
2. Dameshek W. Some speculations on the myeloproliferative syndrome. Blood. 1951;6:372-375.
3. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342:1255-1265.
4. Mesa R, Li C, Schroeder G, Tefferi A. Clinical correlates of splenic histopathology in myelofibrosis with myeloid metaplasia. Blood. 1999;94(10 Suppl 1):a505.
5. Reilly JT. Idiopathic myelofibrosis: pathogenesis, natural history and management. Blood Rev. 1997;11:233-242.
6. Koch CA, Li CY, Mesa RA, Tefferi A. Nonhepatosplenic extra-medullary hematopoiesis: associated diseases, pathology, clinical course, and treatment. Mayo Clin Proc. 2003;78:1223-1233.
7. Anger BR, Seifried E, Scheppach J, Heimpel H. Budd-Chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseases. Klin Wochenschr. 1989;67:818-825.
8. Guardiola P, Esperou H, Cazals-Hatem D, et al. Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. French Society of Bone Marrow Transplantation. Br J Haematol. 1997;98:1004-1009.
9. Mesa RA. Myelofibrosis with myeloid metaplasia: therapeutic options in 2003. Curr Hematol Rep. 2003;2:264-270.
10. Lofvenberg E, Wahlin A. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur J Haematol. 1988;41:375-381.
11. Petti MC, Latagliata R, Spadea T, et al. Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 2002;116:576-581.
12. Mesa RA, Elliott MA, Schroeder G, Tefferi A. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. Mayo Clin Proc. 2004;79:883-889.
13. Tefferi A, Hogan WJ, Wolanskyj AP, et al. A Phase II study of CC-5013 treatment for myelofibrosis with myeloid metaplasia: a preliminary report. Blood. 2004;104:a1505.
14. Faoro LN, Tefferi A, Mesa RA. Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia. Eur J Haematol. 2005;74:117-120.
15. Elliott MA, Chen MG, Silverstein MN, Tefferi A. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol. 1998;103:505-511.
16. Hickling RA. Splenectomy in myeloid metaplasia. Q J Med. 1937;30:253.
17. Silverstein MN, ReMine WH. Sex, splenectomy, and myeloid metaplasia. JAMA. 1974;227:424-426.
18. Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood. 2000;95:2226-2233.
19. Dupriez B, Morel P, Demory J, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system [see comments]. Blood. 1996;88:1013-1018. Available at URL: http://www.Wood-journal. org/cgi/content/abstract/88/3/1013 Access date.
20. Barosi G, Ambrosetti A, Centra A, et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia. Blood. 1998;91:3630-3636.